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Abstract Patients with chest pain have a large impact on
available resources in coronary emergency rooms (CER).
Clinical judgement, ECG, risk scores and biomarkers guide
in risk stratification. We investigated if high-sensitivity tropo-
nin T (HsT) and the HEART Score could contribute to risk
stratification at the CER. All patients with chest pain, without
elevated conventional troponin levels at presentation, were
included. HsT levels were determined at admission (T1), at
4–6 h (T2) and 8–10 h after symptom onset (T3). The HEART
Score was calculated as risk score for the occurrence of a
major adverse cardiac event (MACE). Thirty days after dis-
charge, occurrence of MACE was registered. Eighty-nine
patients were included (overall mean age 61 years (range
20–90)). At presentation, 68 patients (76 %) had a HsT below
cut-off value of 14 ng/l (mean HEART Score 3.7, range 1–9).
Thirty-one of these 68 patients had a HEART Score between
1–3, no MACE occurred in this group. For 3 patients (4 %)
HsT levels increased above 14 ng/l. These 3 patients had
a HEART Score between 4–6. The majority of patients
with chest pain can be safely discharged within 4–6 h
after onset of symptoms using HsT and the HEART
Score. In contrast, patients with initially normal HsT
but a high HEART Score need longer follow-up and
repeat HsT determination.
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Introduction
An increasing number of patients with chest pain are referred
to the casualty department or the coronary emergency room
(CER) to prove or exclude a potentially serious disease such
as an acute coronary syndrome. The challenge lies in rapidly
identifying patients who can safely be discharged from the
CER. In addition, it is necessary to identify patients who need
an aggressive treatment, as part of an acute coronary syn-
drome (ACS), and to take appropriate action as soon as
possible.
The diagnosis of chest pain is made for 47 % of all patients
who are admitted to the cardiology department [1]. These
numbers include patients with ACS. ACS is not responsible
for symptoms in 40% of patients presenting with chest pain in
the CER. The average period of stay of these patients at the
CER in our hospital is currently 11 h. Given the increasing
pressure on the capacity of beds, a shorter length of stay
is warranted. The use of biomarkers in addition to risk
scores can be helpful in optimising the discharge policy
in the CER, through which a shorter duration of stay
might be achieved.
This study was designed to investigate and evaluate the
opportunities for early discharge created by the availability of
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new and more sensitive biomarkers such as high-sensitivity
troponin T assays (HsT) [2–4]. Our study focuses on the
extent to which the HsT in combination with a risk score
contributes to the optimisation of earlier decision-making
and discharge policy (4–6 h) in the CER.
Methods
This study was designed as a prospective cohort study at the
CER of the Rijnstate Hospital in Arnhem in the period from
February 2011 to July 2011. The study was approved by the
local ethics committee and 131 patients initially participated.
The clinical cardiologist and the patients were blinded for HsT
levels.
For this study, all patients presenting to the CER with chest
pain were eligible. Patients could be enrolled if the symptoms
had been present for less than 6 h. Excludedwere patients with
an indication for percutaneous coronary intervention (PCI), as
were patients with ST-elevation myocardial infarction
(STEMI) or non-ST-elevation myocardial infarction
(NSTEMI; typical angina with elevated conventional troponin
T) diagnosed at admission. In addition, patients with chroni-
cally elevated conventional troponin Twere excluded. Finally,
patients who had been treated for a cardiovascular complica-
tion (e.g. heart failure, unstable angina or myocardial infarc-
tion) in the past month were also excluded. All patients were
diagnosed and treated based on conventional troponin T.
According to the discretion of the cardiologist, non-invasive
ischaemia detection could be performed after discharge, dur-
ing follow-up. Myocardial infarction was defined as a rise
and/or fall of conventional troponin with at least 1 value above
30 ng/l [2].
Patients presenting to the CER underwent an initial
clinical evaluation and, as well as the routine laboratory
tests including determination of the conventional troponin
T, an additional sample was taken to determine the HsT
(T1). This was repeated at 4–6 h (T2) and 8–10 h after
symptom onset (T3). If patients presented to the CER
within the window of T2, only the T2 sample was taken.
As with conventional troponin T, HsT was measured on
the E170 module of the Modular Immunoassay (Roche
Diagnostics). We used 14 ng/l as a cut-off value for HsT,
above which results were considered to be ‘increased’.
For the conventional troponin T assay, this value was set
at 30 ng/l.
The 99th percentile for conventional troponin is 10 ng/l.
The 10 % coefficient of variation is set at 30 ng/l. The limit of
detection for conventional troponin is 10 ng/l. The 99th per-
centile for the HsT is 14 ng/l. The coefficient of the variation
of 10 % is set at 13 ng/l. The limit of detection for the HsT is
5 ng/l.
The conventional troponin T does not meet the requirement
that the coefficient of variation at the 99th percentile limit is
below 10 % [5].
In addition, the HEART Score was calculated using the
conventional troponin T value. The HEART Score is a scoring
system for patients presenting to the CER with chest pain [6,
7]. By assigning zero, one or two points to an atypical patient
history, ECG abnormalities, the patient’s age, any risk factors
present, and elevated troponin, patients receive a score on a
scale of 0–10. Patients who score 0-3 points have <1% chance
of developing a cardiac event, those scoring 4–6 points have a
12 % chance, while those patients with a score of ≥7 have on
average a 65 % chance of having a myocardial infarction,
percutaneous coronary intervention or coronary artery bypass
graft, or death within six weeks after presentation (MACE) [6,
7]. Thirty days after discharge, the presence of MACE during
follow-up was registered retrospectively by checking elec-
tronic patient files and personal telephone communication
with the patient, with additional information from the general
practitioner, when needed.
All statistical analyses were performed with SPSS 18.0.
Results
For this study, 131 patients were eligible for enrolment.
Forty-two patients were excluded on basis of the exclusion
criteria. Finally, 89 patients were included in this study, 52
males and 37 females with an overall mean age of 61 years
(range 20–90 years). Admission time to the CER varied
considerably, ranging from 30 min to 6 h after symptom
onset. Baseline characteristics are shown in Table 1. Table 2
shows the range and means of the values of HsT and
conventional troponin T assays measured at the different
time points. Table 3 shows the results of the combination
of HsT and the HEART Score at both T2 and T3, with the
incidence of MACE during follow-up. Patients with HsT<
14 ng/l at T2 and T3, could have MACE during follow-up,
whereas no patients with a HEART Score≤3 had MACE
during follow-up.
Sixty-eight patients out of 89 (76 %) presented with HsT
values below 14 ng/l. Thirty-one of these patients (46%) had a
HEART Score between 1–3. In this group noMACE occurred
within the one-month follow-up period.
Thirty-seven patients (42%)with HsT levels <14 ng/l at T2
had a HEART Score above 3. In this group, 3MACE occurred
in the one-month follow-up (8 %). These 3 patients all had a
PCI because of significant coronary stenosis (angiographical-
ly>70 % and/or fractional flow reserve<0.8) during 30 days
of follow-up.
In 21 patients (24 %) elevated HsT levels were observed at
T2. The probability of a cardiac event in this group was
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substantially higher (28 %). In this group, there were no
patients with a low HEART Score.
In Fig. 1 HsT levels at T2 and T3 are compared. At T2 (4–
6 h after onset of symptoms), 68 patients had a HsT value
less than 14 ng/l. At T3 (8–10 h after start of symptoms), for 3
patients (4 %) HsT levels increased to levels above the cut-off
value of 14 ng/l (average increase in these 3 patients was
30 %). All 3 patients had a moderately increased HEART
Score between 4 and 6. Based on their HEART Score, they
need longer follow-up and repeat HsT determination. One
patient had occurrence of a MACE during follow-up.
Discussion
We investigated the value of the HEART Score as risk strat-
ification model, with the use of conventional troponin T or
HsT in patients with suspected ACS. Our main findings were:
Patients with normal HsT and a HEART Score of≤3 could
safely be discharged at T2, as no MACE occurred. With a
HEART Score of≥4 or more, further monitoring, serial tropo-
nin tests, and/or extra investigation (exercise testing, nuclear
imaging, stress echocardiography) may be required, because a
small proportion of patients have MACE at follow-up. Pa-
tients with elevated HsT at T2 and T3, and/or with a HEART
Score≥7 are at high risk of MACE. These patients should be
admitted and coronary angiography can be considered.
The HEART Score is a specially validated risk score for
patients with chest pain presenting to an emergency depart-
ment in the Netherlands [6, 7]. Other risk scores such as the
GRACE or TIMI risk score are mainly validated in patients
with STEMI and NSTEMI and therefore less useful for this
category of patients [8, 9]. It should be noted that these risk
scores include elevated cardiac markers in their point scoring
system. The HEART Score system makes use of conventional
troponin, and this score system should be further validated,
especially with the current widespread use of HsT in cardiol-
ogy practice.
In our present study, 3 patients (4 %) with initially normal
HsT at T2 showed a rise above the cut-off value of 14 ng/l at
T3. The significance of such an increase is at present unclear,
as some advocate that a 100 % rise is associated with acute,
thrombotic, myocardial infarction. If clinical decision-making
had been based on HsT alone, these 3 patients would not be
identified as high-risk patients at risk for MACE. By also
taking the HEART Score into account, we could identify these
patients at T2. This underscores the importance of combining
risk scores with laboratory tests.
The use of a risk score as the HEART Score can provide
additional information for identifying these patients.
Table 1 Baseline characteristics
N=89
Gender 52 male, 37 female
Age Mean 61 year (range 20–90)
Duration of symptoms Mean 196 min (range 30–360)
HEART Score (using cTnT) Mean 4.15 (range 1–8)
History of vascular disease 39 (44 %)
Diabetes mellitus 17 (19 %)
Smoking 25 (28 %)
Hypertension 29 (32 %)
Family history of vascular disease 30 (34 %)
Hypercholesterolaemia 32 (36 %)
Table 2 Descriptive values of the
conventional Troponin T and the
HsT assays
Conventional Troponin (ng/l) N Minimum Maximum Mean SD
T1 (Entry) 89 16.0 30.0 29.6 1.9
T2 (4 h – 6 h) 89 11.0 333.0 32.9 32.3
T3 (8 h – 10 h) 89 13.0 661.0 41.5 75.0
HsT (ng/l) N Minimum Maximum Mean SD
T1 (Entry) 89 3.0 71.9 10.4 12.4
T2 (4 h – 6 h) 89 3.0 347.0 14.7 37.9
T3 (8 h – 10 h) 89 3.0 675.4 24.4 83.8
Table 3 Combining HsT with HEART Score at T2 and T3 in order to
calculate the risk for MACE
HsT (T2) N HEART Score MACE No MACE
≤ 14 ng/l 31 1–3 0 31
(N=68) 34 4–6 3 31
3 7–10 0 3
≥ 14 ng/l 0 1–3 0 0
(N=21) 13 4–6 3 10
8 7–10 3 5
HsT (T3) N HEART Score MACE No MACE
≤ 14 ng/l 31 1–3 0 31
(N=65) 31 4–6 2 29
3 7–10 0 3
≥ 14 ng/l 0 1–3 0 0
(N=24) 16 4–6 4 12
8 7–10 3 5
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Asmentioned earlier, the HEART Score has been validated
for conventional troponin T and not for HsT. It is to be
expected that by using a high-sensitivity assay in a new
HEART Score, HsT levels will more often be elevated as
compared with conventional troponin T, and hereby the new
risk score could have a higher sensitivity, at the cost of less
specificity. Further studies should provide conclusions regard-
ing the discriminative value of this new risk score.
Despite the fact that cardiac troponins are sensitive and are
specific biochemical markers of myocardial damage, an in-
creased troponin T level occurs in many diseases in which the
heart does not show ischaemia, such as congestive heart
failure, pulmonary embolism, renal failure, acute neurological
disease, myocarditis or sometimes in apparently healthy per-
sons [10]. A clinical observation period may therefore be
required.
Furthermore, the availability of new high-sensitive
assays for troponin T may allow the detection of small
changes in troponin and this test meets the requirements
of the universal definition of myocardial infarction. The
universal definition of acute myocardial infarct states that
there has to be a typical rise and/or fall of biochemical
markers (preferably troponin) with at least 1 value above
the 99th percentile reference limit with at least one of the
following: ischaemic symptoms, ECG changes, patholog-
ical Q waves or imaging evidence of new loss of viable
myocardium motion abnormality [2]. The HsT assay does
meet the requirement that the coefficient of variation at
the 99th percentile limit is below 10 %. The test does not
only appear more sensitive, but is able, even 3 h after
symptom onset, to differentiate whether there is an acute
coronary syndrome or not. Early decision-making is
therefore possible [10]. A problem that may arise is the
possibility of false-positive results of acute coronary
syndrome. However, it is still unclear whether there
should be an absolute or relative increase in troponin
values. In addition, at this moment it is also unclear
how much the troponin values should increase to speak
about an acute coronary syndrome. Some advocate that a
doubling of the serum HsT within 3 h indicates an acute
coronary syndrome whereas others (including the guide-
lines) state that there has to be a rise and/or fall with at
least 1 value above 14 ng/l [11].
Our study is relatively small; therefore, future studies
should be aimed at extending these findings by including
more patients. Only with evidence from larger study popula-
tions, conclusions for clinical decision-making can be drawn.
Our present study is therefore mainly hypothesis generating at
this moment.
In conclusion, our study suggests that patients with chest pain
at the CER, with a negative HsT level together with a low
HEART Score, can be safely discharged from the hospital
Fig 1 eps Changes in serum high
sensitivity troponin T (HsT) in
patients with a level≤14 ng/L at
4-6 h after onset of symptoms
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within 4-6 h after onset of symptoms. The HEARTscore should
be further clinically validated with HsT in larger patient cohorts.
Funding None.
Conflict of interests None declared.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. LMR diagnostic cardiology department 2009, Rijnstate Hospital,
Arnhem, the Netherlands.
2. Thygesen K, Alpert JS, White HD, et al. Third universal definition of
myocardial infarction. Circulation. 2012;126:2020–5
3. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology
and American College of Cardiology guidelines for redefini-
tion of myocardial infarction: how to use existing assays
clinically and for 279 clinical trials. Am Heart J. 2002;144:
981–6
4. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH.
National Academy of Clinical Biochemistry and FCC
Committee for Standardization of Markers of Cardiac
Damage Laboratory Medicine Practice Guidelines: analytical
issues for biochemical markers of acute coronary syndromes.
Circulation. 2007;115:e352–5
5. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus
HA. Analytical validation of a high-sensitivity cardiac troponin T
assay. Clin Chem. 2010;56:254–61
6. Backus BE, Six AJ, Kelder JC, et al. Chest Pain in the
Emergency Room; A Multicenter Validation of the HEART
Score. Crit Pathw Cardiol. 2010;9(3):164–9
7. Six AJ, Backus BE, Kelder JC. Chest pain patients in the
emergency room: value of the HEART score. Neth Heart J.
2008;16:191–6.
8. Morrow DA, Antman EM, Charlesworth A, et al. TIMI Risk
Score for ST-Elevation Myocardial Infarction: A convenient,
Bedside, Clinical Score for Risk Assessment at Presentation.
Circulation. 2000;102:2031–7
9. Fox KAA, Dabbous OH, Goldberg RJ. Prediction of risk of
death and myocardial infarction in the six months after pre-
sentation with acute coronary syndrome: prospective multina-
tional observational study (GRACE). BMJ. 2006;333:1091.
10. Reichlin T, Hochholzer W, Bassetti S, et al. Early Diagnosis of
Myocardial Infarction with Sensitive Cardiac Troponin Assays. N
Engl J Med. 2009;361:858–67
11. Reichlin T, Irfan A, Twerenbold R, et al. Utility of Absolute
and Relative Changes in Cardiac Troponin Concentrations in
the Early Diagnosis of Acute Myocardial Infarction.
Circulation. 2011;124: 136–45.
556 Neth Heart J (2014) 22:552–556
